Transitioning from Suboxone 8 mg Daily to Monthly Long-Acting Injectable Buprenorphine
For a patient stable on Suboxone 8 mg daily, transition directly to monthly long-acting injectable buprenorphine (LAI) without requiring dose escalation or prolonged stabilization periods.
Transition Protocol
Pre-Injection Requirements
The patient should take their last dose of sublingual Suboxone on the same day as the first LAI injection 1. No washout period or dose adjustment is necessary when the patient is already stable on sublingual buprenorphine.
Initial LAI Dosing
Start with 300 mg subcutaneous injection for the first two monthly doses 2. The FDA-approved dosing for Sublocade (the most studied monthly formulation) begins with 300 mg for at least the first two months 1, 2.
- Month 1: 300 mg subcutaneous injection
- Month 2: 300 mg subcutaneous injection
- Month 3 onward: Can continue 300 mg or reduce to 100 mg monthly based on clinical response 2
Why This Approach Works
The 8 mg daily sublingual dose is well within the therapeutic range for LAI transition. Studies demonstrate that patients on sublingual buprenorphine doses ranging from 8-24 mg daily successfully transition to LAI formulations 2. The 300 mg monthly injection provides sustained plasma buprenorphine concentrations that maintain therapeutic coverage throughout the entire dosing interval 2.
Clinical Monitoring
First 24-48 Hours Post-Injection
Monitor for withdrawal symptoms, though these are uncommon when transitioning from stable sublingual therapy. In direct-to-inject protocols (which are more challenging than your scenario), 37% experienced no withdrawal and only 11% had severe withdrawal 3.
Weeks 1-4 After First Injection
- Assess for adequate symptom control (craving suppression, withdrawal prevention)
- Monitor injection site reactions (most common side effect: injection-site pruritus in 9% of patients, typically mild) 2
- Evaluate for common systemic side effects: headache (8-9%), constipation (8-9%), nausea (8-9%) 2
No supplemental sublingual buprenorphine should be provided during LAI treatment 2. The depot formulation is designed to provide complete coverage.
Alternative Formulations
If using Brixadi/Buvidal instead of Sublocade, this formulation offers more flexible dosing options including weekly formulations 4, 5. Brixadi can be initiated directly in patients switching from sublingual buprenorphine and offers multiple dose strengths, potentially allowing for more individualized dosing 5.
Key Advantages of This Transition
Treatment retention is superior with LAI: Studies show 72% of patients continue beyond initial injection, with 68% retained at 30 days and 43% at 90 days 3. The monthly formulation eliminates daily dosing burden, reduces diversion risk, and provides consistent therapeutic levels 2, 4.
Common Pitfalls to Avoid
Do not require dose escalation to 16-24 mg sublingual before switching - this is unnecessary for patients stable on 8 mg 1, 2
Do not start with 100 mg monthly dose - initial dosing should be 300 mg for the first two months to ensure adequate depot formation 2
Do not provide "rescue" sublingual buprenorphine routinely - the depot provides complete coverage and supplemental dosing undermines the LAI approach 2
Do not delay injection waiting for withdrawal symptoms - unlike induction scenarios, patients already on buprenorphine can receive LAI on the same day as their last sublingual dose 1
Special Considerations
The patient's stability on 8 mg daily is actually ideal for LAI transition. This dose demonstrates adequate response to buprenorphine therapy without requiring the higher doses (16-24 mg) that some patients need 1. The LAI formulation will maintain therapeutic plasma levels equivalent to or exceeding their current sublingual regimen 2.